biostudies-literatureUnknown13Huang JBackground: Reliable biomarkers are rare for renal cell carcinoma (RCC) treatment selection. We aimed to discover novel biomarkers for precision medicine. The iron-regulating hormone hepcidin (HAMP) was reportedly increased in RCC patient sera and tissues. However, its potential implication as a prognostic biomarker remains exclusive. Methods: Multiple RNA-seq and cDNA microarray datasets were utilized to analyze gene expression profiles. Hepcidin protein expression was assessed using an ELISA assay in cell culture models. Comparisons of gene expression profiles and patient survival outcomes were conducted using the R package bioinformatics software. Results: Five (HAMP, HBS, ISCA2, STEAP2, and STEAP3) out of 71 iron-modulating genes exhibited consistent changes along Frontiers in pharmacology1080055https://www.ebi.ac.uk/biostudies/studies/S-EPMC9757070biostudies-literatureThe iron-modulating hormone hepcidin is upregulated and associated with poor survival outcomes in renal clear cell carcinoma.PMC9757070Li JCHuang JHolzbeierlein JSong SGan KShen CLi BLiu WfalseThe iron-modulating hormone hepcidin is upregulated and associated with poor survival outcomes in renal clear cell carcinoma.Background: Reliable biomarkers are rare for renal cell carcinoma (RCC) treatment selection. We aimed to discover novel biomarkers for precision medicine. The iron-regulating hormone hepcidin (HAMP) was reportedly increased in RCC patient sera and tissues. However, its potential implication as a prognostic biomarker remains exclusive. Methods: Multiple RNA-seq and cDNA microarray datasets were utilized to analyze gene expression profiles. Hepcidin protein expression was assessed using an ELISA assay in cell culture models. Comparisons of gene expression profiles and patient survival outcomes were conducted using the R package bioinformatics software. Results: Five (HAMP, HBS, ISCA2, STEAP2, and STEAP3) out of 71 iron-modulating genes exhibited consistent changes along 2022-01-01T00:00:00Z20222025-04-03T22:57:20.191Z2024-10-16T19:22:27.546ZS-EPMC97570703653274910.3389/fphar.2022.1080055